Figure 5.

Exploring Drug Response Determinants

(A and B) Response to the pre-mRNA splicing inhibitor indisulam versus expression of its target complex component DCAF15 in the CTRP. Drug response in (B) is measured by the activity area above the dose-response curve, with higher values indicating relative drug sensitivity. A report of increased indisulam sensitivity in hematopoietic cell lines (shown in red) with high DCAF15 expression is readily verified (Han et al., 2017).

(C) Response to the aurora kinase inhibitor alisertib is associated with increased MYC expression in small cell lung cancer lines (Mollaoglu et al., 2017).

(D) Heatmap indicating etoposide drug activity and candidate determinant gene expression in the 100 most sensitive and resistant CTRP cell lines.

(E) Scatterplots of etoposide activity versus candidate determinant gene expression in CTRP cell lines, with hematopoietic cell lines shown in red.

(F) A statistical summary of a multivariate linear model of etoposide response in the CTRP.

(G) A mechanistic scheme indicating how the selected determinants may influence etoposide drug response.